{
    "clinical_study": {
        "@rank": "95866", 
        "arm_group": {
            "arm_group_label": "Tesamorelin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of the study is to determine the PK (tesamorelin) and PD (IGF-1)\n      profiles of tesamorelin after a single 2 mg subcutaneous administration and after repeated\n      administration once daily for 14 consecutive days. Secondary objectives include the\n      evaluation of the safety and tolerability of tesamorelin following multiple subcutaneous\n      injections."
        }, 
        "brief_title": "Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients", 
        "completion_date": {
            "#text": "July 2008", 
            "@type": "Actual"
        }, 
        "condition": "HIV", 
        "condition_browse": {
            "mesh_term": "HIV Seropositivity"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Main Inclusion Criteria:\n\n          -  Male or female, smoker or non-smoker, \u226518 and \u226465 years of age.\n\n          -  HIV-positive with CD4 cell counts >100 cells/mm3 and viral load <10 000 copies/mL.\n\n          -  On stable antiretroviral therapy (ART) regimen for at least 8 weeks prior to the\n             first study drug administration.\n\n          -  Body mass index (BMI) \u2265 20.0 kg/m2.\n\n        Main Exclusion Criteria:\n\n          -  Opportunistic infection or HIV-related disease within 3 months prior to study drug\n             administration.\n\n          -  History of malignancy of any organ or tissue (with the exception of basal cell\n             carcinoma of the skin, in situ carcinoma of the cervix and stable Kaposi not having\n             required treatment for the past 6 months).\n\n          -  For male subjects, suspicion of prostate cancer.\n\n          -  For female subjects, history of breast cancer or strong family history (first degree\n             relative) of breast cancer.\n\n          -  Known hypopituitarism, history of pituitary tumor/surgery, head irradiation or severe\n             head trauma that had affected the somatotropic axis.\n\n          -  Use of any experimental or marketed GH or GRF/GHRH products, GH secretagogues, IGF-1,\n             or insulin-like growth factor binding protein-3 (IGFBP-3) within 6 months prior to\n             study drug administration and throughout the study.\n\n          -  Positive pregnancy test at screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02012556", 
            "org_study_id": "TH9507-CTR-1015"
        }, 
        "intervention": {
            "arm_group_label": "Tesamorelin", 
            "intervention_name": "Tesamorelin", 
            "intervention_type": "Drug", 
            "other_name": "Egrifta"
        }, 
        "intervention_browse": {
            "mesh_term": "Growth Hormone-Releasing Hormone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Montreal", 
                    "country": "Canada", 
                    "state": "Quebec", 
                    "zip": "H3X 2H9"
                }, 
                "name": "Anapharm Montreal"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Study to Evaluate the Pharmacokinetics and the Pharmacodynamics of TH9507 Administered Subcutaneously Once Daily for 14 Consecutive Days in HIV Positive Patients", 
        "overall_official": {
            "affiliation": "Anapharm", 
            "last_name": "Richard Larouche, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the Plasma Concentration versus Time Curve (AUC) of Tesamorelin.", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose on Days 1, 7, 12, 13, and 14, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, and 4 hours post-dose on Day 1, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, 4, 12, and 24 hours post-dose on Day 14."
            }, 
            {
                "measure": "Peak Plasma Concentration (Cmax) of Tesamorelin.", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose on Days 1, 7, 12, 13, and 14, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, and 4 hours post-dose on Day 1, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, 4, 12, and 24 hours post-dose on Day 14."
            }, 
            {
                "measure": "Time to Maximum Plasma Concentration (Tmax) of Tesamorelin.", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose on Days 1, 7, 12, 13, and 14, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, and 4 hours post-dose on Day 1, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, 4, 12, and 24 hours post-dose on Day 14."
            }, 
            {
                "measure": "Apparent Elimination Half-life (T1/2 el) of Tesamorelin.", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose on Days 1, 7, 12, 13, and 14, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, and 4 hours post-dose on Day 1, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, 4, 12, and 24 hours post-dose on Day 14."
            }, 
            {
                "measure": "Plasma Clearance (CI/F) of Tesamorelin.", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose on Days 1, 7, 12, 13, and 14, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, and 4 hours post-dose on Day 1, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, 4, 12, and 24 hours post-dose on Day 14."
            }, 
            {
                "measure": "Apparent Volume of Distribution (Vd/F) of Tesamorelin.", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose on Days 1, 7, 12, 13, and 14, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, and 4 hours post-dose on Day 1, and at 0.05, 0.1, 0.15, 0.2, 0.25, 0.333, 0.5, 0.667, 1, 1.33, 2.5, 4, 12, and 24 hours post-dose on Day 14."
            }, 
            {
                "measure": "Insulin-like Growth Factor-1 (IGF-1) Level at Day 1.", 
                "safety_issue": "No", 
                "time_frame": "Day 1."
            }, 
            {
                "measure": "Insulin-like Growth Factor-1 (IGF-1) Level at Day 7", 
                "safety_issue": "No", 
                "time_frame": "Day 7."
            }, 
            {
                "measure": "Insulin-like Growth Factor-1 (IGF-1) Level at Day 13.", 
                "safety_issue": "No", 
                "time_frame": "Day 13."
            }, 
            {
                "measure": "Insulin-like Growth Factor-1 (IGF-1) Level at Day 14.", 
                "safety_issue": "No", 
                "time_frame": "Day 14."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02012556"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of Subjects with Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "14 days"
        }, 
        "source": "Theratechnologies", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Theratechnologies", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2008", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}